Compare Mesoblast Limited (MESO) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Royal Bank of Canada — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Royal Bank of Canada trades at $192.67 (market cap $265.72B). The key difference: Royal Bank of Canada is far larger — about 146.8× Mesoblast Limited's market cap, and Royal Bank of Canada pays a 2.65% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Royal Bank of Canada for 47 Days on average.
| MESO | RY | |
|---|---|---|
Market Cap | $1.81B | $265.72B |
Volume | 240,620 | 756,291 |
Sector | Health | Financials |
52-Week High | $20.96 | $217.87 |
52-Week Low | $13.19 | $143.64 |
Typical Hold Time | 14 Days | 47 Days |
Enterprise Value | $1.89B | $732.82B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Royal Bank of Canada (RY) trades at $190.56, down 2.95% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 beating estimates of $2.89 (Zacks Investment Research, August 27, 2026). Revenue growth accelerated to $66.53B in 2025, with net income margin improving to 32.01%. The company maintains a solid dividend payout of $1.76 per share, with the next payment scheduled for November 24, 2026.
RY presents a mixed investment case with strong profitability and dividend stability offset by stretched valuations and bearish technical indicators. The 17.2 P/E ratio suggests fair valuation, while analyst consensus leans neutral with 43% buy ratings. Key risks include macroeconomic sensitivity and competitive pressures in financial services. The stock's current technical weakness near support at $189 may present entry opportunities for long-term investors seeking quality banking exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
